CP
AZN icon

Canopy Partners’s AstraZeneca AZN Stock Holding History

Canopy Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$512K Sell
2,702
-19
-0.7% -$3.57K 0.15% 120
2026
Q1 		$537K Buy
2,721
+20
+0.7% +$3.86K 0.18% 103
2025
Q4 		$497K Hold
2,701
– – 0.16% 114
2025
Q3 		$414K Buy
2,701
+203
+8% +$30.7K 0.14% 126
2025
Q2 		$349K Buy
2,498
+31
+1% +$4.34K 0.13% 131
2025
Q1 		$363K Sell
2,467
-11
-0.4% -$1.59K 0.14% 119
2024
Q4 		$325K Sell
2,478
-14
-0.6% -$1.96K 0.12% 135
2024
Q3 		$388K Sell
2,492
-388
-13% -$62.6K 0.17% 113
2024
Q2 		$449K Buy
2,880
+498
+21% +$74.9K 0.21% 98
2024
Q1 		$323K Buy
2,382
+480
+25% +$63.6K 0.16% 122
2023
Q4 		$256K Buy
+1,902
New +$247K 0.16% 128

Other funds holding AZN

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
CDDEC
Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
ZIC
ZWJ Investment Counsel Atlanta, Georgia $3.09B AUM 39.43% 1-Year Est. Return

Canopy Partners's AZN Position: Q2 2026 in Review

Canopy Partners reduced its AstraZeneca (AZN) stake by 0.7% in Q2 2026, selling an estimated $3.57K and leaving 2,702 shares worth $512K. The position accounts for 0.15% of the portfolio, ranked #120.

Canopy Partners first reported a position in AZN in Q4 2023 and has held it in 11 quarters since. The position peaked at $537K in Q1 2026. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Canopy Partners held 2,702 shares of AstraZeneca worth $512K as of Q2 2026.
  • Canopy Partners sold 19 AstraZeneca shares in Q2 2026, an estimated $3.57K.
  • AstraZeneca made up 0.15% of Canopy Partners's portfolio in Q2 2026, its #120 holding.
  • Canopy Partners first reported a position in AstraZeneca in Q4 2023 and has held it in 11 quarters since.
  • Canopy Partners's AstraZeneca position peaked at $537K in Q1 2026.
  • 419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Canopy Partners's 13F filing for Q2 2026, filed 22 Jul 2026.